CVRx公司宣布启动一项名为Benefit-HH的关键心力衰竭临床试验,这项研究具有里程碑意义,旨在评估其Barostim疗法在显著扩展的患者人群中的疗效与安全性。该试验的启动标志着公司在这一重要医疗领域迈出了战略性一步。
CVRx公司宣布启动一项名为Benefit-HH的关键心力衰竭临床试验,这项研究具有里程碑意义,旨在评估其Barostim疗法在显著扩展的患者人群中的疗效与安全性。该试验的启动标志着公司在这一重要医疗领域迈出了战略性一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.